Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CARA

CARA - Cara Therapeutics Inc Stock Price, Fair Value and News

0.28USD+0.03 (+12.00%)Market Closed

Market Summary

CARA
USD0.28+0.03
Market Closed
12.00%

CARA Stock Price

View Fullscreen

CARA RSI Chart

CARA Valuation

Market Cap

15.3M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

0.9

EV/EBITDA

0.37

Price/Free Cashflow

-0.17

CARA Price/Sales (Trailing)

CARA Profitability

EBT Margin

-504.63%

Return on Equity

-411.18%

Return on Assets

-136.01%

Free Cashflow Yield

-589.76%

CARA Fundamentals

CARA Revenue

Revenue (TTM)

16.9M

Rev. Growth (Yr)

-65.37%

Rev. Growth (Qtr)

-28.93%

CARA Earnings

Earnings (TTM)

-122.5M

Earnings Growth (Yr)

-15.12%

Earnings Growth (Qtr)

5.07%

Breaking Down CARA Revenue

Last 7 days

-20%

Last 30 days

-63.6%

Last 90 days

-68.2%

Trailing 12 Months

-92.2%

How does CARA drawdown profile look like?

CARA Financial Health

Current Ratio

5.38

CARA Investor Care

Shares Dilution (1Y)

1.28%

Diluted EPS (TTM)

-2.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202416.9M000
202343.2M27.2M21.2M21.0M
202236.0M48.9M39.4M41.9M
2021107.1M79.1M51.0M23.0M
202023.6M24.0M27.5M135.1M
201917.9M20.2M20.9M19.9M
201802.9M7.9M13.5M
2017361.0K636.0K911.0K911.0K
201602.6M1.3M86.0K
20153.5M3.4M4.7M3.8M
20149.8M7.6M5.4M3.2M
201304.8M8.4M12.0M
20120001.2M

Tracking the Latest Insider Buys and Sells of Cara Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 04, 2024
von moltke lisa
acquired
-
-
150,647
-
Jun 04, 2024
ives jeffrey l.
acquired
-
-
150,647
-
Jun 04, 2024
vogelbaum martin
acquired
-
-
301,295
-
Jun 04, 2024
shiff susan ph.d.
acquired
-
-
150,647
-
Jun 04, 2024
boudreau helen m
acquired
-
-
150,647
-
May 02, 2024
posner christopher
sold
-2,952
0.75
-3,936
president and ceo
Apr 05, 2024
goncalves joana
sold
-2,284
0.83
-2,753
chief medical officer
Apr 05, 2024
terrillion scott
sold
-2,284
0.83
-2,753
sec'y; chief compliance & g.c.
Feb 29, 2024
goncalves joana
sold
-2,930
0.89
-3,293
chief medical officer
Feb 29, 2024
terrillion scott
sold
-2,930
0.89
-3,293
sec'y; chief compliance & g.c.

1–10 of 50

Which funds bought or sold CARA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 21, 2024
Abich Financial Wealth Management LLC
new
-
127
127
-%
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
unchanged
-
259,894
1,416,190
0.01%
May 21, 2024
LRI Investments, LLC
new
-
1,820
1,820
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-69,385
-
-%
May 16, 2024
COMERICA BANK
unchanged
-
6.00
36.00
-%
May 16, 2024
B. Riley Wealth Advisors, Inc.
reduced
-9.75
47,677
93,489
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-31.01
-887
4,833
-%
May 15, 2024
Penserra Capital Management LLC
reduced
-19.63
-1,000
59,000
-%
May 15, 2024
Tudor Investment Corp Et Al
unchanged
-
15,551
84,736
-%
May 15, 2024
MORGAN STANLEY
reduced
-63.89
-121,474
96,335
-%

1–10 of 47

Are Funds Buying or Selling CARA?

Are funds buying CARA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CARA
No. of Funds

Unveiling Cara Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
bain capital life sciences opportunities iii, lp
0%
0
SC 13G/A
Feb 13, 2024
vanguard group inc
4.83%
2,631,067
SC 13G/A
Jan 29, 2024
blackrock inc.
6.5%
3,554,258
SC 13G/A
Jul 25, 2023
vifor (international) ltd
13.7%
7,396,770
SC 13G/A
Jul 07, 2023
blackrock inc.
6.9%
3,701,968
SC 13G/A
Feb 09, 2023
vanguard group inc
5.77%
3,101,724
SC 13G/A
Jan 26, 2023
blackrock inc.
14.4%
7,730,529
SC 13G/A
Jan 20, 2023
blackrock inc.
14.4%
7,730,529
SC 13G/A
Nov 18, 2022
bain capital life sciences opportunities iii, lp
5.0%
2,696,030
SC 13G
Feb 15, 2022
first manhattan co
0.0%
0
SC 13G/A

Recent SEC filings of Cara Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 18, 2024
8-K
Current Report
Jun 12, 2024
8-K
Current Report
Jun 07, 2024
424B5
Prospectus Filed
Jun 07, 2024
8-K
Current Report
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
May 13, 2024
10-Q
Quarterly Report

Peers (Alternatives to Cara Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Cara Therapeutics Inc News

Latest updates
Defense World24 hours ago
MarketWatch18 Jun 202408:55 pm
InvestorPlace13 Jun 202407:00 am
Yahoo Finance13 May 202407:00 am

Cara Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-28.9%2,135,0003,004,0004,866,0006,933,0006,165,0003,261,00010,813,00023,003,0004,790,000821,00020,272,00050,877,66781,483,333112,089,0009,266,0005,634,0008,093,0004,511,0005,785,0005,208,0004,382,000
Operating Expenses-10.7%31,801,00035,611,00033,764,00039,273,00033,815,00034,568,00034,658,00027,475,00032,701,00034,343,00021,396,00030,876,00025,496,00033,799,00026,286,00031,518,00038,094,00034,481,00040,218,00029,350,00027,516,000
  S&GA Expenses3.5%6,816,0006,588,0006,755,0007,545,0006,891,0006,428,0006,912,0007,570,0009,347,00011,512,0005,882,0005,651,0006,365,0006,659,0005,219,0005,410,0004,558,0004,617,0004,226,0004,994,0003,908,000
  R&D Expenses-22.7%21,964,00028,415,00025,451,00030,310,00024,334,00026,010,00024,691,00019,905,00021,273,00022,831,00015,514,00025,225,00019,131,00027,140,00021,067,00026,108,00033,536,00029,864,00035,992,00024,356,00023,608,000
EBITDA Margin-23.8%-5.03-4.06-4.02-3.14-1.97-2.04-2.24-1.80-2.45-3.830.470.10---------
Income Taxes---------------255,000-132,000-182,000-122,000-166,000-330,000-235,000-85,000
Earnings Before Taxes-----------33,382,000-1,013,000-30,745,000-23,301,00078,654,000-16,641,000-25,250,000-29,044,000-28,777,000-33,172,000-23,195,000-22,045,000
EBT Margin-23.8%-5.05-4.08-4.03-3.15-1.98-2.04-2.24-1.81-2.46-3.840.460.10---------
Net Income5.1%-30,696,000-32,337,000-28,032,000-31,479,000-26,665,000-30,339,000-23,180,000-4,206,000-27,749,000-33,382,000-1,013,000-30,745,000-23,301,00078,909,000-16,509,000-25,068,000-28,922,000-28,611,000-32,842,000-22,960,000-21,960,000
Net Income Margin-28.0%-7.23-5.65-5.49-4.11-1.95-2.04-2.25-1.36-2.58-3.840.470.11---------
Free Cashflow-61.1%-31,289,000-19,422,000-19,645,000-20,445,000-34,618,000-23,510,000-25,192,000-4,503,000-25,568,000-1,412,000-14,283,000-21,172,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-28.4%90.00126115134153182214227224247225221250271147169196233264150171
  Current Assets-30.1%81.00116101125143169187176152173171164188195133142133166203125144
    Cash Equivalents-9.2%47.0052.0063.0058.0048.0064.0043.0047.0022.0014.0023.0023.0023.0032.0076.0057.0017.0019.0035.0019.0015.00
  Inventory-2.8%3.003.003.003.004.002.002.003.002.003.00-----------
  Net PPE6.8%4.003.001.000.000.000.000.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities-12.3%60.0069.00---23.00---------------
  Current Liabilities-41.0%15.0026.0023.0025.0017.0023.0028.0021.0018.0018.0016.0015.0017.0018.0017.0025.0033.0043.0048.0040.0042.00
Shareholder's Equity-47.8%30.0057.0086.00109137159185204204228207203230249128141160187212100115
  Retained Earnings-4.5%-715-684-652-624-592-566-535-512-508-480-447-446-415-392-471-454-429-400-372-339-316
  Additional Paid-In Capital0.5%745742738734731727723719714709699650646641599595590587584439431
Shares Outstanding0.3%55.0054.0054.0054.0054.0054.0054.0054.0054.0051.0050.0050.00---------
Float----131---417---696---726---784-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-75.3%-30,453-17,370-19,645-20,445-34,618-23,510-25,192-4,503-25,525-1,245-14,116-21,005-23,72182,088-21,620-27,652-38,303-31,166-25,637-24,896-27,526
  Share Based Compensation-7.1%3,3453,6013,3343,4423,3533,8013,5744,6555,7048,7844,3933,4764,1324,0653,3054,6192,8463,3862,9334,0152,234
Cashflow From Investing185.9%25,951-30,20523,15532,80317,70844,42321,17629,67733,431-53,58114,43320,52813,869-164,15539,53967,38236,95914,738-96,88125,22826,399
Cashflow From Financing-101.9%-68536,4751,116-56022.001041823.0045,28833929368838,46939520175.0028.00138,3683,974234
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CARA Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 2,135$ 6,165
Operating expenses:  
Cost of goods sold6202,590
Research and development21,96424,334
General and administrative6,8166,891
Restructuring2,401 
Total operating expenses31,80133,815
Operating loss(29,666)(27,650)
Other income, net952985
Non-cash interest expense on liability related to sales of future royalties and milestones(1,982) 
Net loss$ (30,696)$ (26,665)
Net loss per share:  
Basic$ (0.56)$ (0.49)
Diluted$ (0.56)$ (0.49)
Weighted average shares:  
Basic54,588,09053,872,038
Diluted54,588,09053,872,038
Other comprehensive income, net of tax of $0:  
Change in unrealized gains on available-for-sale marketable securities$ 69$ 571
Total comprehensive loss(30,627)(26,094)
Collaborative revenue  
Revenue:  
Total revenue7882,750
Commercial supply revenue  
Revenue:  
Total revenue6403,191
Royalty revenue  
Revenue:  
Total revenue 125
Clinical compound revenue  
Revenue:  
Total revenue84$ 99
Other revenue  
Revenue:  
Total revenue$ 623 

CARA Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 46,996$ 51,775
Marketable securities22,77748,983
Accounts receivable, net - related party1,7182,765
Inventory, net2,7412,821
Income tax receivable697697
Other receivables506555
Prepaid expenses5,7908,154
Restricted cash 408
Total current assets81,225116,158
Operating lease right-of-use assets3,8264,864
Property and equipment, net3,5483,322
Restricted cash, non-current1,5001,500
Total assets90,099125,844
Current liabilities:  
Accounts payable and accrued expenses14,87525,592
Operating lease liability, current220 
Total current liabilities15,09525,592
Liability related to sales of future royalties and milestones, net38,37637,079
Operating lease liability, non-current6,8256,088
Total liabilities60,29668,759
Commitments and contingencies (Note 17)
Stockholders' equity:  
Preferred stock; $0.001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023, zero shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock; $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023, 54,667,079 shares and 54,480,704 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively5454
Additional paid-in capital745,381742,036
Accumulated deficit(715,441)(684,745)
Accumulated other comprehensive loss(191)(260)
Total stockholders' equity29,80357,085
Total liabilities and stockholders' equity$ 90,099$ 125,844
CARA
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.
 CEO
 WEBSITEcaratherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES106

Cara Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Cara Therapeutics Inc? What does CARA stand for in stocks?

CARA is the stock ticker symbol of Cara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cara Therapeutics Inc (CARA)?

As of Fri Jun 21 2024, market cap of Cara Therapeutics Inc is 15.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CARA stock?

You can check CARA's fair value in chart for subscribers.

What is the fair value of CARA stock?

You can check CARA's fair value in chart for subscribers. The fair value of Cara Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cara Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CARA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CARA is over valued or under valued. Whether Cara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CARA.

What is Cara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, CARA's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 0.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CARA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cara Therapeutics Inc's stock?

In the past 10 years, Cara Therapeutics Inc has provided -0.336 (multiply by 100 for percentage) rate of return.